Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: May 2, 2024 · CIK: 1581178
Sentiment: neutral
Topics: filing, corporate-update, press-release
TL;DR
Eupraxia Pharma filed a 6-K on May 2nd, including a press release. Check Form 40-F for annual reports.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 2, 2024, reporting information as of that date. The filing indicates the company is a foreign private issuer and will file annual reports under Form 40-F. It includes a press release dated May 2, 2024, as Exhibit 99.1.
Why It Matters
This filing provides updated information for investors and regulatory bodies regarding Eupraxia Pharmaceuticals' reporting status and includes a recent press release.
Risk Assessment
Risk Level: low — This is a routine filing providing updated corporate information and a press release, not indicating significant new risks.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- May 2, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- Form 40-F (document) — Annual report filing type
- Exhibit 99.1 (document) — Included press release
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K is to report information as of May 2, 2024, and to include Exhibit 99.1, a press release dated May 2, 2024.
What type of annual report does Eupraxia Pharmaceuticals Inc. file?
Eupraxia Pharmaceuticals Inc. files its annual reports under cover of Form 40-F.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
What is the principal executive office address of Eupraxia Pharmaceuticals Inc.?
The principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is the Commission File Number for Eupraxia Pharmaceuticals Inc.?
The Commission File Number for Eupraxia Pharmaceuticals Inc. is 001-41923.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2024-05-02 07:01:53
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 25KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000510.txt ( ) — 69KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: May 2, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer